The overview
[Chart: Fortune Business Insights, Grand View Research, MarketsandMarkets, Global Market Insights, Allied, 360iResearch, Straits (2021-2026 releases). See the live document for the chart.]
| Workload (from our ranking) | Market | Latest size | Forecast | Growth a year |
|---|---|---|---|---|
| 1. EU MDR and US submissions | Device regulatory affairs outsourcing | $2.1B (2024, device segment) to $4.6B (2021) | $8.1B (2031) | 6 to 7% |
| 1. EU MDR and US submissions | Medical device CRO | no current base found | $14.0 to 15.1B (2030) | 6.4 to 9.6% |
| 1. EU MDR and US submissions | Device testing, inspection, and certification | $3.2B (2024, TIC) to $10.6B (2023, all testing) | $5.1 to 13.5B (2028 to 2030) | 4.9 to 8.5% |
| 2. CAPA, complaints, and design controls | Medical device QMS software | $1.2B (2025) | $2.5B (2032) | 10.6% |
| 2 and 4. Complaints and postmarket | Medical device complaint management | $8.9B (2025) | $13.3 to 19.2B (2030 to 2034) | about 8.8 to 8.9% |
| Cross-cutting | AI in regulatory affairs (all life sciences) | $1.3 to 1.5B (2024 to 2025) | $6.7 to 7.2B (2033 to 2034) | about 18.6% |
These markets are smaller than pharma’s, where clinical trial services alone are about $58 to 60 billion. Medtech spending is spread across more specialized vendors. Software and AI again grow fastest.
Regulatory outsourcing, CROs, and testing
Regulatory affairs outsourcing.
- Global Market Insights sizes all healthcare regulatory affairs outsourcing at $7.5 billion in 2024 ($8.1 billion in 2025), reaching $15.7 billion by 2034. Medical device companies were $2.1 billion of that in 2024, growing 7.1% a year.
- Allied Market Research gives an older, device-specific figure: $4.6 billion in 2021, reaching $8.1 billion by 2031.
- Our reading: the EU MDR workload described in our companion article, with its new reports and longer reviews, is a likely driver of this demand.
Medical device CROs. Grand View forecasts $14.0 billion by 2030 (9% a year). Precedence (2022) forecast $15.1 billion by 2030, from $7.3 billion in 2020. We found no reliable current base-year figure.
Testing, inspection, and certification.
- Grand View sizes the narrow medical device TIC market at $3.2 billion in 2024, reaching $5.1 billion by 2030.
- MarketsandMarkets uses a broader testing scope: $10.6 billion in 2023, reaching $13.5 billion by 2028.
Company revenue as a reality check (2025). The large testing groups do not report medical revenue separately, so they show scale rather than device-specific size:
| Company | 2025 revenue | Medtech note |
|---|---|---|
| SGS | CHF 6.9 billion | no medical breakout |
| Intertek | £3.4 billion | cites “more demand for medical devices”; bought a medical device testing lab |
| UL Solutions | $3.1 billion | no medical breakout |
Quality, complaints, postmarket, and AI
QMS software. 360iResearch puts medical device quality management software at $1.2 billion in 2025, growing 10.6% a year to $2.5 billion by 2032. The broader life sciences QMS market, mostly pharma, is about $3.7 billion (Grand View). FDA’s new QMSR, in force since February 2026, is likely to add to demand.
Supplier anchors:
- One private QMS vendor passed $200 million in annual recurring revenue in 2025, with more than 1,250 customers.
- One listed life sciences cloud vendor, whose products include quality software, reported $3.2 billion of total revenue. It does not report medtech separately.
Complaint management. This is the largest workload market we found that serves a single function.
- Fortune Business Insights: $8.9 billion in 2025, reaching $19.2 billion by 2034 (8.9% a year).
- Grand View: $13.3 billion by 2030 (8.8% a year).
- These figures likely include services as well as software. They fit the workload data: CAPA and complaint files are among FDA’s top warning letter citations, and FDA receives more than 2 million medical device reports a year.
Medical device vigilance. Some firms publish figures of $66 to 90 billion. These are far larger than any related market and likely use a very broad scope, so we do not rely on them.
AI in regulatory affairs (all life sciences, including devices):
- Grand View: $1.3 billion in 2024, reaching $6.7 billion by 2033 (18.6% a year).
- Straits: $1.5 billion in 2025, reaching $7.2 billion by 2034.
It is small today but growing more than twice as fast as the outsourcing markets.
Why estimates differ
- Scope. “Vigilance” and “testing” estimates range from narrow to very broad, which explains the very large figures some firms publish.
- Age. Several device-specific figures date from 2020 to 2022. We mark their years.
- Shared markets. Regulatory outsourcing and AI figures often cover pharma and devices together.
- No company breakouts. Testing groups and software vendors do not report medtech revenue separately.
Using market data in AI and RAG
- Store each estimate with its firm, scope, base year, and release date.
- Mark figures that cover all life sciences rather than devices only.
- Show ranges and leave out outliers, with a note explaining why.
- Map each market to the workload it serves, as in the overview table.
Common mistakes
- Using a 2020 forecast as a current market size.
- Treating a life sciences total as a device-only figure.
- Citing the very large vigilance estimates without checking their scope.
- Adding markets that overlap, such as complaint management and QMS software.
Checklist
- Two or more sources per market where available
- Scope and base year recorded
- Device-only and life sciences figures separated
- Outliers flagged
How AskDona helps
AskDona sits where these markets overlap: the documents behind technical files, clinical evaluations, complaints, CAPAs, and labels. Whether the work is done in-house or by a consultant, test lab, or CRO, AskDona checks it against the rules and source records and cites the passage behind each finding.
Run a sample vendor deliverable evidence check
AskDona shows the evidence; your regulatory and quality teams decide.
Editor’s note. This article is general information, not investment advice. Market sizes are commercial research estimates with different scopes and base years; some date from 2020 to 2022 and are marked as such. Company figures come from 2025 annual results.
FAQ
How big is the medical device regulatory outsourcing market? About $2.1 billion in 2024 for device companies (Global Market Insights). Older estimates go up to $4.6 billion.
How big is the medical device CRO market? Forecasts put it at $14 to 15 billion by 2030.
How big is the complaint management market? About $8.9 billion in 2025, growing about 9% a year.
What is growing fastest? AI in regulatory affairs, at about 18.6% a year, followed by QMS software at about 10.6%.
References
All pages opened and checked by October 31, 2026.
| Source | What it supports |
|---|---|
| Global Market Insights: Healthcare RA outsourcing | $7.5B total, $2.1B device segment |
| Allied: Medical device RA outsourcing | $4.6B (2021), $8.1B (2031) |
| Grand View via GII: Medical device CRO | $14.0B by 2030 |
| Precedence via BioSpace: Medical device CRO | $7.3B (2020), $15.1B (2030) |
| Grand View via GII: Device TIC | $3.2B (2024) |
| MarketsandMarkets: Medical device testing | $10.6B (2023) |
| 360iResearch via GII: Device QMS software | $1.2B (2025) |
| Grand View via GII: Life sciences QMS | $3.7B (2025) |
| Fortune Business Insights: Complaint management | $8.9B (2025) |
| Grand View via GII: Complaint management | $13.3B by 2030 |
| Grand View via GII: AI in regulatory affairs | $1.3B (2024) |
| Straits: AI in regulatory affairs | $1.5B (2025) |
| UL Solutions: 2025 results | Revenue |
| Intertek: 2025 results | Revenue, medical device demand |
| SGS: 2025 results | Revenue |
| Private QMS vendor: $200M ARR | QMS vendor scale |
| Life sciences cloud vendor: FY2026 results | Revenue |